960 results on '"Luchini, Claudio"'
Search Results
2. Subgrading of G2 Pancreatic Neuroendocrine Tumors as 2A (Ki67 3% to < 10%) Versus 2B (10% to ≤ 20%) Identifies Behaviorally Distinct Subsets in Keeping with the Evolving Management Protocols
3. ASO Author Reflections: Prognostic Value of Subgrading G2 Pancreatic Neuroendocrine Tumors as 2A versus 2B
4. Impact of extra-ampullary duodenal adenocarcinoma subtypes on surgical and oncological outcomes following pancreaticoduodenectomy
5. Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting
6. The tumour immune microenvironment and microbiome of pancreatic intraductal papillary mucinous neoplasms
7. Pancreatic steatosis and metabolic pancreatic disease: a new entity?
8. Recurrent gastric amphicrine tumor with neuroendocrine and pancreatic acinar cell differentiation and somatic MEN1 inactivation arisen during immunotherapy
9. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma
10. Gastric Carcinoma in Autoimmune Gastritis: A Histopathologic and Molecular Study
11. DNA Methylation Profiling Enables Accurate Classification of Nonductal Primary Pancreatic Neoplasms
12. Characterization and digital spatial deconvolution of the immune microenvironment of intraductal oncocytic papillary neoplasms (IOPN) of the pancreas
13. Comprehensive Characterization of Intraductal Oncocytic Papillary Neoplasm of the Pancreas: A Systematic and Critical Review
14. Fusion genes in pancreatic tumors
15. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion
16. Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial
17. Correction to: Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting
18. Either High or Low Risk: The Acinar Score at the Resection Margin Dichotomizes the Risk Spectrum of Pancreas-specific Complications After Pancreatoduodenectomy
19. CA19.9 Response and Tumor Size Predict Recurrence Following Post-neoadjuvant Pancreatectomy in Initially Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
20. Integrative characterization of intraductal tubulopapillary neoplasm (ITPN) of the pancreas and associated invasive adenocarcinoma
21. Systematic review of challenging issues in pathology of intraductal papillary mucinous neoplasms
22. Genetic and non-genetic risk factors for early-onset pancreatic cancer
23. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial
24. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors
25. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years’ experience of association studies to understand the genetic architecture of pancreatic cancer
26. Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA/ACRG classes
27. Juvenile polyposis diagnosed with an integrated histological, immunohistochemical and molecular approach identifying new SMAD4 pathogenic variants
28. Evidence of glucose absorption in a neoformed intestine
29. Loss of FGFR4 promotes the malignant phenotype of PDAC
30. Familial and Inherited Pancreatic Cancer
31. Multiple Endocrine Neoplasia 1 Syndrome
32. Intraductal Papillary Mucinous Neoplasm (IPMN)
33. Mucinous Neoplasms
34. Serous Neoplasms
35. Pathology of Biliary Tract Cancers
36. Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells
37. Transcriptome analysis of primary sporadic neuroendocrine tumours of the intestine identified three different molecular subgroups
38. Rare histotypes of epithelial biliary tract tumors: A literature review
39. MCL1 as putative target in pancreatoblastoma
40. “Pure” hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms
41. Infiltration pattern predicts metastasis and progression better than the T-stage and grade in pancreatic neuroendocrine tumors: a proposal for a novel infiltration-based morphologic grading
42. Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring
43. Circulating tumour DNA: a challenging innovation to develop “precision onco-surgery” in pancreatic adenocarcinoma
44. Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases
45. CD13 is a useful tool in the differential diagnosis of meningiomas with potential biological and prognostic implications
46. Importance of Nodal Metastases Location in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: Results from a Prospective, Lymphadenectomy Protocol
47. Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites
48. Spliceosomic dysregulation in pancreatic cancer uncovers splicing factors PRPF8 and RBMX as novel candidate actionable targets
49. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
50. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.